Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan

Modern Rheumatology

Volumn 15, Issue 6, 2005, Pages 397-404

  Mori, Masaaki ^a   Takei, Syuji ^b   Imagawa, Tomoyuki ^a   Imanaka, Hiroyuki ^b   Maeno, Nobuaki ^b   Kurosawa, Rumiko ^a   Kawano, Yoshifumi ^b   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Childhood; Etanercept; Methotrexate; Serum cytokine; Tumor necrosis factor (TNF) alpha

Indexed keywords

ETANERCEPT; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPAN; JOINT CONTRACTURE; JUVENILE RHEUMATOID ARTHRITIS; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 31144473862     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-005-0431-9     Document Type: Article

References (39)

1. RE Petty, TR Southwood, J Baum, E Bhettay, DN Glass, P Manners et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991-4. 9779856 1:STN:280:DyaK1cvltFWgtA%3D%3D
2. RE Petty, P Malleson, Epidemiology of juvenile rheumatoid arthriti.s World Pediatr Child Care 1987;3:205-10.
3. BM Ansell, Prognosis in juvenile arthritis. Adv Exp Med Biol 1999;455:27-33. 10599320 1:STN:280:DC%2BD3c%2FmslChtQ%3D%3D
4. EH Giannini, EJ Brewer, N Kuzmina, A Shaikov, A Maximov, I Vorontsov et al. Methotrexate in resistant juvenile rheumatoid arthritis: Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992;326:1043-9. 1549149 1:STN:280:By2C1MrjsF0%3D
5. A Reiff, B Shaham, BP Wood, BH Bernstein, P Stanley, IS Szer, High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995;13:113-8. 7774090 1:STN:280:ByqB1M3ktlQ%3D
6. LD Graham, BL Myones, RF Rivas-Chacon, LM Pachman, Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992;120:468-73. 1538301 1:STN:280:By2C28nps1A%3D
7. P Woo, TR Southwood, AM Prieur, CJ Dore, J Grainger, J David et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis Arthritis Rheum 2000;43:1849-57. 10.1002/ 1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F 10943876 1:CAS:528:DC%2BD3cXmtFKju7o%3D
8. CA Wallace, DD Sherry, Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992;19:1604-7. 1464876 1:STN:280:ByyC3c%2FntVA%3D
9. A Reiff, B Shaham, BP Wood, BH Bernstein, P Stanley, IS Szer, High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995;13:113-8. 7774090 1:STN:280:ByqB1M3ktlQ%3D
10. CA Wallace 1998 The use of methotrexate in childhood rheumatic diseases Arthritis Rheum 41 381-91 10.1002/ 1529-0131(199803)41:3<381::AID-ART2>3.0.CO;2-3 9506564 1:CAS:528:DyaK1cXitF2isbc%3D
11. KM Mohler, PR Sleath, JN Fitzner, DP Cerretti, M Alderson, SS Kerwar, Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994;370:218-20. 10.1038/370218a0 8028669 1:CAS:528:DyaK2cXmsVKitbg%3D A1994NX97100053
12. KM Mohler, DS Torrance, CA Smith, RG Goodwin, KE Stremler, VP Fung, Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61. 8393046 1:CAS:528:DyaK3sXmtVWmsL4%3D
13. LW Moreland, SW Baumgartner, MH Schiff, EA Tindall, RM Fleischmann, AL Weaver et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor(p75)-Fc fusion protein. N Engl J Med 1997;337:141-7. 10.1056/NEJM199707173370301 9219699 1:CAS:528:DyaK2sXlt1Smur0%3D
14. LW Moreland, MH Schiff, SW Baumgartner, EA Tindall, RM Fleischmann, KJ Bulpitt et al. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999;130:478-86. 10075615 1:CAS:528:DyaK1MXitFChs7Y%3D
15. ME Weinblatt, JM Kremer, AD Bankhurst, KJ Bulpitt, RM Fleischmann, RI Fox et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1993;340:253-9. 10.1056/ NEJM199901283400401 9920948 1:CAS:528:DyaK1MXht1Wqsbk%3D
16. G Singh, BH Athreya, JF Fries, DP Goldsmith, Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9. 7986222 1:STN:280:ByqD2sjls1U%3D
17. J Pouchot, N Ruperto, I Lemelle, D Sommelet, E Grouteau, L David et al. The French version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19 (4 Suppl 23):S60-5. 11510333 1:STN:280:DC%2BD3MvmsFyrsw%3D%3D
18. EH Giannini, N Ruperto, A Ravelli, DJ Lovell, DT Felson, A Martini, Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. 9214419 1:STN:280:ByiA2Mjgs1w%3D
19. DJ Lovell, EH Giannini, A Reiff, GD Cawkwell, ED Silverman, JJ Nocton et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9. 10.1056/NEJM200003163421103 10717011 1:CAS:528:DC%2BD3cXit1Smu7k%3D
20. EH Giannini, JT Cassidy, Methotrexate in juvenile rheumatoid arthritis: do the benefits outweigh the risks? Drug Saf 1993;9:325-39. 8280401 1:STN:280:ByuC3cjltVQ%3D A1993MF14900002
21. DMFM van der Heijde, MA van't Hof, PLCM van Riel, LAM Theunisse, EW Lubberts, MA van Leeuwen et al. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20. 2256738 1:STN:280:By6D2snmtFQ%3D
22. MLL Prevoo, MA van't Tof, HH Kuper, MA van Leeuwen, LBA van de Putte, PL van Riel, Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44-8. 7818570 1:STN:280:ByqC3MfjvFI%3D
23. AM van Gestel, MLL Prevoo, MA van't Tof, MH van Rijswijk, LBA van de Putte, PL van Riel, Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40. 8546736 1:STN:280:BymC3szisF0%3D
24. JM Dayer, B Beutler, A Cerami, Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8. 10.1084/ jem.162.6.2163 2999289 1:CAS:528:DyaL28Xmslanug%3D%3D
25. DR Bertolini, GE Nedwin, TS Bringman, DD Smith, GR Mundy, Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;319:516-8. 10.1038/319516a0 3511389 1:CAS:528:DyaL28XhtVOlu70%3D A1986AYW3600065
26. J Saklatvala, Tumour necrosis factor a stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-9. 10.1038/322547a0 3736671 1:CAS:528:DyaL28XltlWqsr4%3D A1986D523100054
27. FM Brennan, D Chantry, A Jackson, R Maini, M Feldmann, Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7. 2569055 1:STN:280:BiaA38bpvVY%3D A1989AH61800005
28. SC Thornton, SB Por, R Penny, M Richter, L Shelley, SN Breit, Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor-alpha. Clin Exp Immunol 1991;86:79-86. 1914237 1:CAS:528:DyaK3MXmslOrsLw%3D
29. EJU von Asmuth, CJ van der Linden, JFM Leeuwenberg, WA Buurman, Involvement of the CD11b/CD18 integrin, but not of the endothelial cell adhesion molecules ELAM-1 and ICAM-1 in tumor necrosis factor-alpha-induced neutrophil toxicity. J Immunol 1991;147: 3869-75. 1719092 1:CAS:528:DyaK38Xls1yksQ%3D%3D
30. JC Beckham, DS Caldwell, BL Peterson, AM Pippen, MS Currie, FJ Keefe et al. Disease severity in rheumatoid arthritis: Relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353-61. 10.1007/BF00920793 1430106 1:STN:280:ByyD2MrivFE%3D
31. AA Grom, KJ Murray, L Luyrink, H Emery, MH Passo, DN Glass, et al. Pattern of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum 1996;39:1703-10. 8843861 1:STN:280:ByiD3c%2FotVE%3D
32. H Mangge, H Kenzian, S Gallistl, G Neuwirth, P Liebmann, W Kaulfersch et al. Serum cytokines in juvenile rheumatoid arthritis: Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995;38:211-20. 7848311 1:STN:280:ByqC2M7gsV0%3D
33. BA Eberhard, RM Laxer, U Andersson, ED Silverman, Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 1994;96: 260-6. 8187333 1:CAS:528:DyaK2cXkvVSksL4%3D
34. LW Moreland, SB Cohen, SW Baumgartner, EA Tindall, K Bulpitt, R Martin et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44. 11409115 1:CAS:528:DC%2BD3MXkvVOhu7g%3D
35. JM Bathon, RW Martin, RM Fleischmann, JR Tesser, MH Schiff, EC Keystone et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93. 10.1056/ NEJM200011303432201 11096165 1:CAS:528:DC%2BD3cXovVeltLg%3D
36. MC Genovese, JM Bathon, RW Martin, RM Fleischmann, JR Tesser, MH Schiff et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50. 12115173 1:CAS:528:DC%2BD38Xltlantbk%3D
37. DA Kietz, PH Pepmueller, TL Moore, Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol 2001;28:360-2. 11246677 1:CAS:528:DC%2BD3MXhs1Slsrs%3D
38. H Schmeling, K Mathony, V John, G Keysser, S Burdach, G Horneff, A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: A pilot study. Ann Rheum Dis 2001;60: 410-2. 10.1136/ard.60.4.410 11247875 1:CAS:528:DC%2BD3MXislylsrY%3D
39. PE Lipsky, DM van der Heijde, EW St Clair, DE Furst, FC Breedveld, JR Kalden et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602. 10.1056/ NEJM200011303432202 11096166 1:CAS:528:DC%2BD3cXovVeltLk%3D